Literature DB >> 7557946

Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor.

Y Morimitsu1, C C Hsia, M Kojiro, E Tabor.   

Abstract

Expression of transforming growth factor-alpha (TGF-alpha) and its receptor, the epidermal growth factor receptor (EGFR), in hepatocellular carcinomas (HCCs) and adjacent nontumorous livers from 25 Japanese patients were examined using immunoperoxidase staining of paraffin-embedded sections. TGF-alpha was detected in 24 of 25 (96%) HCCs and 23 of 24 (96%) available adjacent nontumorous livers. EGFR was detected in 16 of 25 (64%) HCCs and 17 of 24 (71%) adjacent nontumorous livers. TGF-alpha and EGFR were not detected by immunohistochemical staining in normal livers. Fifteen of 25 HCCs contained an apparent area of a second tumor (two of the 15 also contained a third tumor) that had a less-differentiated histological grade developing within or adjacent to the first tumor. In those cases, staining in the less-differentiated area of tumor was usually less intense than in the more highly differentiated area (80% of cases for TGF-alpha; 91% for EGFR). These data confirm that increased expression of TGF-alpha and EGFR occur frequently in human HCC. Furthermore, the detection of greater staining in more highly differentiated portions of the tumors suggests that increased expression of TGF-alpha and EGFR may be events of the early stages of human hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7557946     DOI: 10.1016/0046-8177(95)90275-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

Review 1.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.

Authors:  Jörg Haupenthal; Verena Bihrer; Huedayi Korkusuz; Otto Kollmar; Christian Schmithals; Susanne Kriener; Knut Engels; Thomas Pleli; Alexander Benz; Marta Canamero; Thomas Longerich; Bernd Kronenberger; Swantje Richter; Oliver Waidmann; Thomas J Vogl; Stefan Zeuzem; Albrecht Piiper
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

3.  Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma.

Authors:  Wenjia Wang; Xiao-Pin Ma; Zhuqing Shi; Pengyin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexi Ge Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hongjie Yu; Jielin Sun; S Lilly Zheng; Long Yu; Jianfeng Xu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Authors:  Barham K Abu Dayyeh; May Yang; Bryan C Fuchs; Daniel L Karl; Suguru Yamada; John J Sninsky; Thomas R O'Brien; Jules L Dienstag; Kenneth K Tanabe; Raymond T Chung
Journal:  Gastroenterology       Date:  2011-03-24       Impact factor: 22.682

5.  Roles of EGFR-Stat3 signal pathway in carcinogenesis of experimental hepatoma in rats.

Authors:  Xiao Tang Yu; Shi Neng Zhu; Zu De Xu; Xi Qi Hu; Teng Fang Zhu; Jie Qing Chen; Shi Lun Lu
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-10       Impact factor: 4.553

6.  Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.

Authors:  Aloísio Felipe-Silva; Alda Wakamatsu; Cinthya Dos Santos Cirqueira; Venâncio Avancini Ferreira Alves
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

7.  New pharmacological developments in the treatment of hepatocellular cancer.

Authors:  Niraj J Gusani; Yixing Jiang; Eric T Kimchi; Kevin F Staveley-O'Carroll; Hua Cheng; Jaffer A Ajani
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 8.  Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.

Authors:  Khanh Nguyen; Kerri Jack; Weijing Sun
Journal:  Diseases       Date:  2015-12-25

9.  Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.

Authors:  Sumit Siddharth; Panjamurthy Kuppusamy; Qitong Wu; Arumugam Nagalingam; Neeraj K Saxena; Dipali Sharma
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

10.  A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients.

Authors:  Masaya Suenaga; Suguru Yamada; Tsutomu Fujii; Bryan C Fuchs; Norio Okumura; Mitsuro Kanda; Daisuke Kobayashi; Chie Tanaka; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Shuji Nomoto; Michitaka Fujiwara; Shin Takeda; Kazuhiko Hayashi; Kenneth K Tanabe; Hidemi Goto; Yasuhiro Kodera
Journal:  Onco Targets Ther       Date:  2013-12-13       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.